CN Mobile Logo

Search form


Hematologic Malignancies

Hematologic Malignancies

Single-agent use of blinatumomab resulted in anti-leukemic activity in patients with tyrosine kinase inhibitor–relapsed or refractory Philadelphia chromosome positive B-precursor acute lymphoblastic leukemia.

Global inequities in childhood leukemia survival have narrowed in recent years but still persist, according to data from CONCORD-2.

Treatment with ponatinib yielded better overall survival compared with allogeneic stem cell transplantation in patients with chronic phase chronic myeloid leukemia with a T315I mutation.

Combined treatment with lenalidomide, bortezomib, and dexamethasone plus transplantation significantly delayed progression in patients with multiple myeloma.

Low pretreatment disease burden improved durability of CAR T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia.

The JAK2 and FLT3 inhibitor pacritinib induced significant and sustained spleen volume reduction and symptom reduction in patients with myelofibrosis.

Patients with relapsed or refractory multiple myeloma experienced significant indirect social costs from their disease, in addition to the direct costs.


Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.